Skip to main content

Table 1 (abstract O16). Patient characteristics, adverse events and JADAS at baseline and last follow-up in ETAt and MTX cohort

From: Proceedings of the 27th European Paediatric Rheumatology Congress (PReS 2021)

 

ETA cohort

N=2885

MTX cohort

N=1517

Female, n (%)

1937 (67.1)

1023 (67.4)

Disease Duration, years, mean (SD)

4.1 (3.7)

2.1 (2.8)

ANA positive, n (%)

1388 (48.1)

727 (47.9)

HLA B 27 positive, n (%)

685 (23.7)

265 (17.5)

AE, n; rate/100PY (95%CI)

2531; 38.5 (37.1-40.1)

1354; 34 (32.9-36.6)

SAE, n; rate/100PY (95%CI)

243; 3.7 (3.2-4.2)

50; 1.3 (0.9-1.6)

Serious infections, n; rate/100PY (95%CI)

57; 2.0 (1.5-2.6)

7; 0.5 (0.2-1.0)

Baseline JADAS 10, mean (SD)

15.2 (7.5)

13.8 (7.1)

Last observation JADAS 10, mean (SD)

6.3 (7.2)

5.3 (6.8)